3,740 Shares in Axon Enterprise, Inc $AXON Purchased by Daiichi Life Insurance Co. Ltd.

Daiichi Life Insurance Co. Ltd. acquired a new stake in Axon Enterprise, Inc (NASDAQ:AXON) in the second quarter, HoldingsChannel.com reports. The fund acquired 3,740 shares of the biotechnology company’s stock, valued at approximately $2,097,000.

Several other institutional investors also recently made changes to their positions in AXON. Creative Financial Designs Inc. ADV purchased a new stake in Axon Enterprise during the fourth quarter worth about $28,000. Camelot Portfolios LLC purchased a new position in Axon Enterprise in the fourth quarter valued at about $30,000. Keating Financial Advisory Services Inc. purchased a new position in Axon Enterprise in the second quarter valued at about $31,000. AlphaCentric Advisors LLC acquired a new stake in shares of Axon Enterprise during the 4th quarter valued at approximately $34,000. Finally, Darwin Wealth Management LLC acquired a new stake in shares of Axon Enterprise during the 2nd quarter valued at approximately $37,000. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Elizabeth Reid Coughlin sold 1,554 shares of Axon Enterprise stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $485.00, for a total transaction of $753,690.00. Following the transaction, the insider owned 34,024 shares in the company, valued at approximately $16,501,640. The trade was a 4.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CRO Cameron Brooks sold 1,242 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $500.00, for a total value of $621,000.00. Following the transaction, the executive directly owned 49,710 shares in the company, valued at $24,855,000. This trade represents a 2.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 66,989 shares of company stock valued at $35,216,932 in the last 90 days. 4.20% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on AXON. Morgan Stanley upped their price target on Axon Enterprise from $600.00 to $640.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. UBS Group upped their target price on Axon Enterprise from $440.00 to $600.00 and gave the company a “neutral” rating in a report on Thursday, August 6th. Needham & Company LLC restated a “buy” rating on shares of Axon Enterprise in a research report on Thursday, August 6th. Piper Sandler raised their target price on shares of Axon Enterprise from $724.00 to $732.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Finally, Zacks Research downgraded shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a report on Friday, July 10th. Thirteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $730.92.

Axon Enterprise Price Performance

Shares of NASDAQ:AXON opened at $627.75 on Monday. The company has a quick ratio of 1.80, a current ratio of 2.15 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $51.00 billion, a P/E ratio of 260.48, a P/E/G ratio of 10.19 and a beta of 1.39. Axon Enterprise, Inc has a 52-week low of $339.01 and a 52-week high of $794.29. The stock’s fifty day simple moving average is $543.11 and its 200-day simple moving average is $476.99.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Tuesday, August 4th. The biotechnology company reported $1.88 EPS for the quarter, topping the consensus estimate of $1.84 by $0.04. Axon Enterprise had a net margin of 6.19% and a return on equity of 2.84%. The firm had revenue of $904.39 million during the quarter, compared to analysts’ expectations of $876.42 million. During the same period in the previous year, the company earned $2.12 EPS. Axon Enterprise’s revenue for the quarter was up 35.3% on a year-over-year basis. As a group, equities research analysts forecast that Axon Enterprise, Inc will post 2.04 earnings per share for the current fiscal year.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.